Clinical pharmacokinetics of fenofibrate

Telford, Michael

doi:10.1185/030079902125001532

Cited by 6 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug is excreted unchanged in urines either as fenofibric acid or as its A c c e p t e d M a n u s c r i p t glucuronide conjugate. No hepatic microsomal metabolism is involved, not being fenofibric acid a substrate for CYP3A4 (102).…”

Section: Fibratesmentioning

confidence: 99%

Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?

et al. 2018

View full text Add to dashboard Cite

Inflammatory changes are responsible for maintenance of the atherosclerotic process and may underlie some of the most feared vascular complications. Among the multiple mechanisms of inflammation, the arterial deposition of lipids and particularly of cholesterol crystals is the one responsible for the activation of inflammasome NLRP3, followed by the rise of circulating markers, mainly C-reactive protein (CRP). Elevation of lipoproteins, LDL but also VLDL and remnants, associates with increased inflammatory changes and coronary risk. Lipid lowering medications can reduce cholesterolemia and CRP: patients with elevations of both are at greatest cardiovascular (CV) risk and receive maximum benefit from therapy. Evaluation of the major drug series indicates that statins exert the largest LDL and CRP reduction, accompanied by reduced CV events. Other drugs, mainly active on the triglyceride/HDL axis, for example, PPAR agonists, may improve CRP and the lipid pattern, especially in patients with metabolic syndrome. PCSK9 antagonists, the newest most potent medications, do not induce significant changes in inflammatory markers, but patients with the highest baseline CRP levels show the best CV risk reduction. Parallel evaluation of lipids and inflammatory changes clearly indicates a significant link, both guiding to patients at highest risk, and to the best pharmacological approach. Key messages Lipid lowering agents with "pleiotropic" effects provide a more effective approach to CV prevention In CANTOS study, patients achieving on-treatment hsCRP concentrations ≤2 mg/L had a higher benefit in terms of reduction in major CV events The anti-inflammatory activity of PCSK9 antagonists appears to be of a minimal extent.

show abstract

Section: Fibratesmentioning

confidence: 99%

Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In contrast, fenofibrate does not have any significant effects on the pharmacokinetics of pravastatin (Gustavson et al 2005) or simvastatin (Bergman et al 2004). Furthermore, in vivo data suggest that fenofibric acid does not undergo significant oxidative metabolism by cytochrome P450 and does not inhibit most cytochrome P450 isoforms (Keating and Ormrod 2002; Telford and Elisaf 2003). …”

Section: Fibrate–statin Combination Therapymentioning

confidence: 99%

Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review

Τζιόμαλος¹,

Athyros²

2006

International Journal of Nanomedicine

View full text Add to dashboard Cite

Cardiovascular disease is the major cause of mortality worldwide and accounts for approximately 40% of all deaths. Dyslipidemia is one of the primary causes of atherosclerosis and effective interventions to correct dyslipidemia should form an integral component of any strategy aimed at preventing cardiovascular disease. Fibrates have played a major role in the treatment of hyperlipidemia for more than two decades. Fenofibrate is one of the most commonly used fibrates worldwide. Since fenofibrate was first introduced in clinical practice, a major drawback has been its low bioavailability when taken under fasting conditions. Insoluble Drug Delivery-Microparticle fenofibrate is a new formulation that has an equivalent extent of absorption under fed or fasting conditions. In this review, we will discuss the clinical pharmacology of fenofibrate, with particular emphasis on this novel formulation, as well as its lipid-modulating and pleiotropic actions. We will also analyze the major trial that evaluated fibrates for primary and secondary prevention of cardiovascular disease, the safety and efficacy profile of fibrate–statin combination treatment, and the current recommendations regarding the use of fibrates in clinical practice.

show abstract

Hyperlipidemia Management for Primary Care

Reamy¹,

Henley²

2008

View full text Add to dashboard Cite

Clinical pharmacokinetics of fenofibrate

Cited by 6 publications

References 7 publications

Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?

Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?

Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review

Hyperlipidemia Management for Primary Care

Contact Info

Product

Resources

About